Clinical Trial Update: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating nivolumab plus standard of care versus standard of care in first-line colorectal cancer has completed (Phase 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colorectal Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-02-25